Moderna (MRNA) Panoramica del titolo
Moderna, Inc. è un'azienda biotecnologica che fornisce farmaci a base di RNA messaggero negli Stati Uniti, in Europa e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
MRNA Community Fair Values
Create NarrativeSee what 265 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$175
FV
17.1% sottovalutato sconto intrinseco1.1k
users have viewed this narrative2users have liked this narrative
4users have commented on this narrative
29users have followed this narrative
Concorrenti di Moderna, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$145.13 |
| Massimo di 52 settimane | US$176.66 |
| Minimo di 52 settimane | US$22.28 |
| Beta | 0.90 |
| Variazione di 1 mese | 168.41% |
| Variazione a 3 mesi | 208.59% |
| Variazione di 1 anno | 472.50% |
| Variazione a 3 anni | 27.50% |
| Variazione a 5 anni | -60.85% |
| Variazione dall'IPO | 680.27% |
Notizie e aggiornamenti recenti
Seeking Alpha • Aug 19
Moderna: Stock Surging On Cancer 'Vaccine' Breakthrough, I See More Volatility Ahead
Summary Moderna surged over 130% after its Phase 3 melanoma trial for Intismeran, in combo with Keytruda, met key endpoints. Intismeran demonstrated statistically significant improvements in recurrence-free and distant metastasis-free survival, validating MRNA's individualized mRNA cancer therapy approach. Despite the breakthrough, I assign a Hold rating, urging caution until full Phase 3 data is released and regulatory paths clarify. Long-term upside exists if intismeran expands into larger oncology markets, but near-term valuation remains tied to further clinical and commercial validation. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 10
MRNA: Future Upside Will Hinge On New Flu Vaccine Rollout
Analysts have lifted their fair value estimate for Moderna stock from about $66.29 to roughly $78.89. This reflects updated models that incorporate higher assumed revenue growth, a slightly higher discount rate, modestly lower profit margin expectations, and a higher future P/E multiple in line with recent increases in Street price targets across major research firms.Recent updates
Seeking Alpha • Aug 19
Moderna: Stock Surging On Cancer 'Vaccine' Breakthrough, I See More Volatility Ahead
Summary Moderna surged over 130% after its Phase 3 melanoma trial for Intismeran, in combo with Keytruda, met key endpoints. Intismeran demonstrated statistically significant improvements in recurrence-free and distant metastasis-free survival, validating MRNA's individualized mRNA cancer therapy approach. Despite the breakthrough, I assign a Hold rating, urging caution until full Phase 3 data is released and regulatory paths clarify. Long-term upside exists if intismeran expands into larger oncology markets, but near-term valuation remains tied to further clinical and commercial validation. Read the full article on Seeking AlphaAggiornamento narrativa • Aug 10
MRNA: Future Upside Will Hinge On New Flu Vaccine Rollout
Analysts have lifted their fair value estimate for Moderna stock from about $66.29 to roughly $78.89. This reflects updated models that incorporate higher assumed revenue growth, a slightly higher discount rate, modestly lower profit margin expectations, and a higher future P/E multiple in line with recent increases in Street price targets across major research firms.
Aggiornamento narrativa • Jul 27
MRNA: Flu Revenue Delays And Regulatory Timing Will Constrain Future Upside
Analysts have lifted their fair value estimate for Moderna stock from $22.00 to $25.00, reflecting updated assumptions around revenue growth, profitability, and future P/E multiples in light of a series of higher Street price targets and supportive commentary on the company's vaccine pipeline. Analyst Commentary Recent research coverage of Moderna shows a mix of optimism around the vaccine portfolio and caution around execution, timing of revenues, and valuation.Aggiornamento narrativa • Jul 13
MRNA: Flu Approval Uncertainty And Delayed Vaccine Revenues Will Restrain Upside
Analysts have nudged their fair value estimate for Moderna to $22.00, citing a series of recently higher Street price targets that reflect increased attention on upcoming vaccine catalysts, sector momentum, and company specific earnings drivers. Analyst Commentary Street research on Moderna reflects a mix of optimism around the vaccine pipeline and caution around execution, earnings visibility, and valuation.
Aggiornamento narrativa • Jun 29
MRNA: Flu Approval Progress Will Still Limit Long Term Upside
Moderna's updated analyst price target framework reflects a modest fair value adjustment to about $44.25 per share, along with higher modeled revenue growth and profit margins and a lower future P/E multiple, as analysts factor in supportive regulatory commentary on the mRNA flu program and incremental optimism around the broader vaccine pipeline. Analyst Commentary Recent Street research around Moderna highlights a mix of optimism tied to the mRNA flu and broader vaccine pipeline, and caution around timing, clinical data gaps, and execution risk.Articolo di analisi • Jun 21
Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing
Moderna (MRNA) is back in focus after a unanimous FDA advisory panel vote that its investigational mRNA flu vaccine, mFlusiva, has a favorable benefit risk profile in adults 50 and older. See our latest analysis for Moderna. Moderna’s recent regulatory win has arrived after a sharp rebound in the stock, with a 1-year total shareholder return of 146.95% and a year to date share price return of 107.26%, while the 3 and 5 year total shareholder returns remain significantly lower. This suggests...Aggiornamento narrativa • Jun 15
MRNA: Flu Review And Pipeline Execution Risk Are Expected To Restrain Upside
Moderna's updated analyst price target edges higher, with the model fair value moving from $21.00 to about $21.09 as analysts factor in slightly stronger revenue growth expectations and potential upside from norovirus vaccine penetration. Analyst Commentary Recent Street research on Moderna clusters around cautious optimism, with several firms adjusting price targets while still highlighting meaningful risks tied to execution and future growth drivers, especially in vaccines beyond Covid.Aggiornamento narrativa • Jun 01
MRNA: Flu Review And Litigation Overhang Will Continue To Restrain Upside
Analysts raised Moderna’s fair value estimate from $12.00 to $21.00, citing a series of higher Street price targets and updated assumptions for margins, litigation risk, and future P/E multiples. Analyst Commentary Recent Street research around Moderna has centered on two themes: valuation reset after the litigation settlement and differing views on how much residual legal and execution risk still matters for the stock.Aggiornamento narrativa • May 13
MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome
Narrative Update on Moderna Analysts have collectively raised their Moderna price targets by low to mid single digit dollar amounts, citing updated models that reflect recent litigation settlements, FDA progress on the flu vaccine, and oncology pipeline developments. Together, these factors support a lower fair value estimate of $66.29, a slightly higher discount rate of 7.21%, adjusted revenue growth expectations of 52.59%, a profit margin of 4.12%, and a future P/E assumption of 107.40x.Aggiornamento narrativa • Apr 27
MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside
Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple. Analyst Commentary Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine.Aggiornamento narrativa • Apr 13
MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside
Analysts have nudged Moderna's average price target higher by $5, reflecting a mix of renewed confidence in the company's vaccine pipeline after the FDA's reconsideration of its flu shot application and reduced litigation overhang following recent settlement developments. Analyst Commentary Recent research on Moderna clusters around two main themes for you to watch closely: valuation reset around the vaccine pipeline and lingering legal and execution risks tied to the COVID and flu franchises.Aggiornamento narrativa • Mar 30
MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside
Analyst price targets for Moderna have generally shifted higher, with several firms moving into a $30 to $69 range as they factor in the recent Arbutus settlement, the FDA’s renewed review of the mRNA-1010 flu vaccine with an August 5 PDUFA date, and updated product and oncology pipeline assumptions. Analyst Commentary Street research on Moderna currently reflects a mixed but generally cautious stance, even as litigation and regulatory headlines have reduced some overhangs.Aggiornamento narrativa • Mar 16
MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside
Analysts have trimmed Moderna's implied fair value from $15.00 to $12.00 as they factor in a higher discount rate, more moderate profit margins and updated views on revenue growth following recent litigation settlements and regulatory updates. Analyst Commentary Street research around Moderna centers on two themes that matter for you as an investor: the clean-up of legal overhangs and how much confidence to place in the broader vaccine and oncology pipeline.Aggiornamento narrativa • Mar 02
MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision
Our fair value estimate for Moderna has inched up by about $1.65 per share to $91.97 as analysts update their models around higher projected product sales, a more constructive FDA review path for the mRNA-1010 flu vaccine with an August 5 PDUFA date, and refreshed views on the broader late stage pipeline including oncology. Analyst Commentary Street research on Moderna has leaned more constructive around the updated regulatory path for flu vaccine mRNA-1010, the broader late stage pipeline, and recent quarterly disclosures.Articolo di analisi • Feb 17
Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90
As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest annual results with some very strong...Aggiornamento narrativa • Feb 16
MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes
Analysts have nudged their average price target for Moderna higher by about $3, reflecting updated views on long term revenue potential, profit margins and a higher future P/E multiple following recent research on COVID demand, the broader vaccine pipeline and legal outcomes. Analyst Commentary Recent Street research on Moderna highlights a mix of caution and growing optimism, with several bullish analysts adjusting their models after company updates, legal developments and new financing disclosures.Articolo di analisi • Feb 02
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Despite an already strong run, Moderna, Inc. ( NASDAQ:MRNA ) shares have been powering on, with a gain of 43% in the...Aggiornamento narrativa • Feb 01
MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside
The analyst price target for Moderna has increased by about $2 to $38.80, as analysts incorporate updated assumptions for slightly stronger revenue growth, modestly better profit margins, a marginally lower discount rate, and a slightly reduced future P/E multiple. Analyst Commentary Recent Street research on Moderna shows a mix of cautious optimism and ongoing concern.Aggiornamento narrativa • Jan 18
MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential
Narrative update We trim our analyst price target for Moderna from about US$121 to roughly US$87 as analysts factor in lower profit margin expectations, a higher discount rate, cautious views on COVID-related revenue visibility, and a more binary risk profile around key late stage vaccine data, even as some models reflect higher revenue growth assumptions and updated financing terms. Analyst Commentary Recent Street research on Moderna points to a mixed backdrop, with several firms reaffirming cautious stances while still recognizing specific areas where execution and funding choices could support long term value creation.Aggiornamento narrativa • Jan 04
MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation
Analysts have modestly lifted their price targets on Moderna, with recent revisions such as $15 to $18, $16 to $17, and $32 to $30. These changes collectively reflect slightly improved conviction in the company’s long term revenue growth, gross margin expansion, and strengthened liquidity following new Ares financing, despite ongoing profitability and litigation risks.Aggiornamento narrativa • Dec 21
MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks
Analysts have modestly raised their price target on Moderna to align with a slightly higher fair value estimate of about $36.75, citing incremental improvements in long term revenue growth and profitability assumptions supported by recent Investor and Analyst Day updates, revised 2026 to 2028 guidance, and Ares financing. Analyst Commentary Recent Street research reflects a cautious but incrementally more constructive stance toward Moderna, with several firms refining their models following Investor and Analyst Day presentations and the announcement of new financing.Articolo di analisi • Dec 19
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise
Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 28% share price jump in the last...Aggiornamento narrativa • Dec 07
MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk
Analysts have modestly lowered their price target on Moderna to about $35.78 from $37.32 per share, reflecting slightly softer long term growth and valuation assumptions. This comes even as recent Investor and Analyst Day updates, new debt financing and evolving oncology data support a more stable cash outlook and gradual margin improvement.Aggiornamento narrativa • Nov 23
MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts
Analysts have revised their fair value estimate for Moderna down from approximately $40.30 to $37.32. They cited the company’s updated revenue growth projections and cost outlook, despite improvements in profit margins and continued progress across its commercial and research pipelines.Aggiornamento narrativa • Nov 07
MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties
Moderna's analyst price target was reduced from $18 to $15, as analysts pointed to lower US vaccination trends and ongoing regulatory uncertainties that are impacting the outlook for its vaccine franchises. Analyst Commentary Recent analyst notes have reflected both cautious and optimistic perspectives on Moderna's outlook.Aggiornamento narrativa • Oct 23
Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts
Moderna’s analyst price target has been revised downward from $44.25 to $40.30. Analysts cite lower projected revenue growth along with persistent regulatory and profitability challenges, which have been reflected in recent industry commentary.Aggiornamento narrativa • Sep 04
Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential
Moderna’s consensus price target was held at $44.25 as analysts cited declining US vaccine demand, increased regulatory hurdles for flu/COVID combinations, delayed UK deliveries impacting 2025 guidance, and persistent uncertainty around mRNA vaccine approvals. Analyst Commentary Lowered US vaccination trends for both COVID and flu are reducing addressable market expectations for Moderna’s vaccines.Nuova narrativa • May 02
MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK
Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing andSeeking Alpha • Apr 22
More Downside For Moderna Before The Breakthrough
Summary Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires investor patience, with key vaccines in Phase 3 trials but regulatory approvals potentially years away. Financials are sound enough to support long term research, with a significant cash buffer, but oncology research faces regulatory and technical challenges. Shares are likely to go down before any uptrend (2-3 years horizon). Read the full article on Seeking AlphaSeeking Alpha • Mar 31
FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)
Summary Moderna's stock dropped over 10% after the FDA's Dr. Peter Marks resigned, signaling potential increased regulatory scrutiny on vaccines. Moderna's financial health remains strong, with ~$9 billion in cash and investments, but the stock is down 65% since my August rating downgrade. Despite pipeline progress, regulatory uncertainty and intense competition from Pfizer and GSK pose significant risks to Moderna's revenue outlook. Given the negative public perception of mRNA technology and regulatory risks, I downgrade MRNA to "Hold" until more clarity emerges. Read the full article on Seeking AlphaSeeking Alpha • Mar 06
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Summary Moderna, Inc.'s stock surged 16% yesterday after a German court ruled Pfizer and BioNTech may have violated Moderna's COVID-19 vaccine patent, potentially leading to compensation. Despite the ruling, Pfizer and BioNTech will appeal, while previous court decisions have invalidated related patents, complicating Moderna's legal victory. MRNA's business struggles post-pandemic, with declining revenues and few new products, have made litigation a potentially critical revenue source, which I'd call a red flag. The ongoing legal battles resemble other prolonged patent disputes, highlighting the challenges in monetizing groundbreaking technologies like mRNA and CRISPR. If Moderna had released ten products since 2022, instead of one, it's unlikely yesterday's news would have moved its share price, but this reflects the new reality of messenger-RNA, a technology that hasn't lived up to the hype — yet. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
Moderna, Inc.: Working Hard But Competition Is Working Harder
Summary MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition. Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Read the full article on Seeking Alpha
Nuova narrativa • Feb 09
Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks
Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.Rendimenti per gli azionisti
| MRNA | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 125.1% | 6.3% | -1.2% |
| 1Y | 472.5% | 47.2% | 18.3% |
Ritorno vs Industria: MRNA ha superato il US Biotechs che ha restituito 47.2 % nell'ultimo anno.
Rendimento vs Mercato: MRNA ha superato il mercato US che ha restituito 18.3 % nell'ultimo anno.
Volatilità dei prezzi
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | 51.7% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di MRNA è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di MRNA è aumentata da 27% a 52% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2010 | 4,700 | Stéphane Bancel | www.modernatx.com |
Moderna, Inc. è un'azienda biotecnologica che fornisce farmaci a base di RNA messaggero negli Stati Uniti, in Europa e a livello internazionale. I vaccini respiratori dell'azienda comprendono spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, influenza stagionale, vaccino combinato e vaccino contro l'influenza pandemica; i vaccini latenti comprendono i vaccini contro il citomegalovirus, il virus di epstein-barr e il virus dell'immunodeficienza umana; i virus enterici comprendono il norovirus; i vaccini per la salute pubblica consistono in vaccini contro Zika, Nipah e Mpox; e i vaccini contro le malattie batteriche, come il vaccino contro il lyme. Fornisce anche prodotti terapeutici per l'oncologia, come l'autogene intismeran, la terapia dell'antigene del cancro, il t-cell engager e il cell therapy enhancer; e prodotti per le malattie rare, tra cui l'acidemia propionica e metilmalonica e la fibrosi cistica.
Moderna, Inc. Riepilogo dei fondamenti
| MRNA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$57.94b |
| Utili (TTM) | -US$3.15b |
| Ricavi(TTM) | US$2.23b |
26.0x
Rapporto P/S-18.4x
Rapporto P/EMRNA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MRNA Conto economico (TTM) | |
|---|---|
| Ricavi | US$2.23b |
| Costo del fatturato | US$3.70b |
| Profitto lordo | -US$1.47b |
| Altre spese | US$1.68b |
| Utili | -US$3.15b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -7.89 |
| Margine lordo | -66.02% |
| Margine di profitto netto | -141.43% |
| Rapporto debito/patrimonio netto | 8.7% |
Come si è comportato MRNA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/24 07:34 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Moderna, Inc. è coperta da 42 analisti. 21 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | Argus Research Company |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |